Similar articles

• Vitamin K-dependent procoagulant in cancer cells: a potential target for the antimetastatic effect of warfarin?

  Donati MB, Roncaglioni MC, Falanga A, Casali B, Semeraro N. Donati MB, et al. Haemostasis. 1986;16(3-4):288-94. doi: 10.1159/000215300. Haemostasis. 1986. PMID: 3530903
• Cancer cell procoagulants and their pharmacological modulation.

  Donati MB, Semeraro N. Donati MB, et al. Haemostasis. 1984;14(5):422-9. doi: 10.1159/000215100. Haemostasis. 1984. PMID: 6398243 Review.
• Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency.

  Colucci M, Delaini F, de Bellis Vitti G, Locati D, Poggi A, Semeraro N, Donati MB. Colucci M, et al. Biochem Pharmacol. 1983 Jun 1;32(11):1689-91. doi: 10.1016/0006-2952(83)90110-7. Biochem Pharmacol. 1983. PMID: 6870908
• Cancer cell procoagulant: a novel vitamin K-dependent activity.

  Delaini F, Colucci M, De Bellis Vitti G, Locati D, Poggi A, Semeraro N, Donati MB. Delaini F, et al. Thromb Res. 1981 Nov 1;24(3):263-6. doi: 10.1016/0049-3848(81)90097-9. Thromb Res. 1981. PMID: 7336382 No abstract available.
• Possible strategies for antimetastastic therapy.

  Honn KV, Onoda JM, Menter DG, Cavanaugh PG, Taylor JD, Crissman JD, Ryan RE, Sloane BF. Honn KV, et al. Prog Clin Biol Res. 1986;212:217-49. Prog Clin Biol Res. 1986. PMID: 3520578 Review. No abstract available.